6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
mortality B-NonOSE_AE
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
thoughts O
and O
behaviors I-OSE_Labeled_AE
in O
adolescents O
and O
young O
adults O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
, O
including O
stroke B-NonOSE_AE
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
5.3 O
] O
* O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
5.4 O
] O
* O
Metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( O
hyperglycemia B-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
5 O
. O

5 O
] O
* O
Tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.6 O
] O
* O
Hypotension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.7 O
] O
* O
Falls B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.8 O
] O
* O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
children O
and O
adolescents O
) O
[ O
see O
Warnings O
and O
Precautions O
5.9 O
] O
* O
Leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
and O
agranulocytosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.10 O
] O
* O
Cataracts B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.11 O
] O
* O
QT B-NonOSE_AE
Prolongation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.12 O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.13 O
] O
* O
Hypothyroidism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.14 O
] O
* O
Hyperprolactinemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.15 O
] O
* O
Potential O
for O
cognitive B-OSE_Labeled_AE
and O
motor O
impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.16 O
] O
* O
Body B-NonOSE_AE
temperature I-NonOSE_AE
regulation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.17 O
] O
* O
Dysphagia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.18 O
] O
* O
Discontinuation B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.19 O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
twice O
placebo O
) O
: O
Adults O
: O
somnolence O
, O
dry O
mouth O
, O
dizziness O
, O
constipation O
, O
asthenia O
, O
abdominal O
pain O
, O
postural O
hypotension O
, O
pharyngitis O
, O
weight O
gain O
, O
lethargy O
, O
ALT O
increased O
, O
dyspepsia O
( O
6.1 O
) O
Children O
and O
Adolescents O
: O
somnolence O
, O
dizziness O
, O
fatigue O
, O
increased O
appetite O
, O
nausea O
, O
vomiting O
, O
dry O
mouth O
, O
tachycardia O
, O
weight O
increased O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Study O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adults O
: O
The O
information O
below O
is O
derived O
from O
a O
clinical O
trial O
database O
for O
SEROQUEL O
consisting O
of O
over O
4300 O
patients O
. O

This O
database O
includes O
698 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
405 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
monotherapy O
and O
adjunct O
therapy O
) O
, O
646 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
maintenance O
treatment O
of O
bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
adjunct O
therapy O
, O
and O
approximately O
2600 O
patients O
and/or O
normal O
subjects O
exposed O
to O
1 O
or O
more O
doses O
of O
SEROQUEL O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
. O

Of O
these O
approximately O
4300 O
subjects O
, O
approximately O
4000 O
( O
2300 O
in O
schizophrenia B-Not_AE_Candidate
, O
405 O
in O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
, O
698 O
in O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
and O
646 O
for O
the O
maintenance O
treatment O
of O
bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
) O
were O
patients O
who O
participated O
in O
multiple O
dose O
effectiveness O
trials O
, O
and O
their O
experience O
corresponded O
to O
approximately O
2400 O
patient-years O
. O

The O
conditions O
and O
duration O
of O
treatment O
with O
SEROQUEL O
varied O
greatly O
and O
included O
( O
in O
overlapping O
categories O
) O
open-label O
and O
double-blind O
phases O
of O
studies O
, O
inpatients O
and O
outpatients O
, O
fixed-dose O
and O
dose-titration O
studies O
, O
and O
short-term O
or O
longer-term O
exposure O
. O

Adverse O
reactions O
were O
assessed O
by O
collecting O
adverse O
events O
, O
results O
of O
physical O
examinations O
, O
vital O
signs O
, O
weights O
, O
laboratory O
analyses O
, O
ECGs O
, O
and O
results O
of O
ophthalmologic O
examinations O
. O

The O
stated O
frequencies O
of O
adverse O
reactions O
represent O
the O
proportion O
of O
individuals O
who O
experienced O
, O
at O
least O
once O
, O
a O
treatment-emergent O
adverse O
reaction O
of O
the O
type O
listed O
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Schizophrenia B-Not_AE_Candidate
: O
Overall O
, O
there O
was O
little O
difference O
in O
the O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
( O
4 O
% O
for O
SEROQUEL O
vs O
. O
3 O
% O
for O
placebo O
) O
in O
a O
pool O
of O
controlled O
trials O
. O

However O
, O
discontinuations O
due O
to O
somnolence B-OSE_Labeled_AE
( O
0.8 O
% O
SEROQUEL O
vs O
. O
0 O
% O
placebo O
) O
and O
hypotension B-OSE_Labeled_AE
( O
0.4 O
% O
SEROQUEL O
vs O
. O
0 O
% O
placebo O
) O
were O
considered O
to O
be O
drug O
related O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
and O
5.19 O
) O
] O
. O

Bipolar B-Not_AE_Candidate
Disorder I-Not_AE_Candidate
: O
Mania B-Not_AE_Candidate
: O
Overall O
, O
discontinuations O
due O
to O
adverse O
reactions O
were O
5.7 O
% O
for O
SEROQUEL O
vs O
. O
5.1 O
% O
for O
placebo O
in O
monotherapy O
and O
3.6 O
% O
for O
SEROQUEL O
vs O
. O
5.9 O
% O
for O
placebo O
in O
adjunct O
therapy O
. O

Depression B-Not_AE_Candidate
: O
Overall O
, O
discontinuations O
due O
to O
adverse O
reactions O
were O
12.3 O
% O
for O
SEROQUEL O
300 O
mg O
vs O
. O
19.0 O
% O
for O
SEROQUEL O
600 O
mg O
and O
5.2 O
% O
for O
placebo O
. O

Commonly O
Observed O
Adverse O
Reactions O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
: O
In O
the O
acute O
therapy O
of O
schizophrenia B-Not_AE_Candidate
( O
up O
to O
6 O
weeks O
) O
and O
bipolar O
mania O
( O
up O
to O
12 O
weeks O
) O
trials O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
monotherapy O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
observed O
at O
a O
rate O
on O
SEROQUEL O
at O
least O
twice O
that O
of O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
and O
dyspepsia B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
Among O
SEROQUEL O
Treated O
Patients O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
: O
The O
prescriber O
should O
be O
aware O
that O
the O
figures O
in O
the O
tables O
and O
tabulations O
can O
not O
be O
used O
to O
predict O
the O
incidence O
of O
side O
effects O
in O
the O
course O
of O
usual O
medical O
practice O
where O
patient O
characteristics O
and O
other O
factors O
differ O
from O
those O
that O
prevailed O
in O
the O
clinical O
trials O
. O

Similarly O
, O
the O
cited O
frequencies O
can O
not O
be O
compared O
with O
figures O
obtained O
from O
other O
clinical O
investigations O
involving O
different O
treatments O
, O
uses O
, O
and O
investigators O
. O

The O
cited O
figures O
, O
however O
, O
do O
provide O
the O
prescribing O
physician O
with O
some O
basis O
for O
estimating O
the O
relative O
contribution O
of O
drug O
and O
nondrug O
factors O
to O
the O
side O
effect O
incidence O
in O
the O
population O
studied O
. O

Table O
9 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
adverse O
reactions O
that O
occurred O
during O
acute O
therapy O
of O
schizophrenia B-Not_AE_Candidate
( O
up O
to O
6 O
weeks O
) O
and O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
up O
to O
12 O
weeks O
) O
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
ranging O
from O
75 O
to O
800 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Table O
9 O
: O
Adverse O
Reaction O
Incidence O
in O
3- O
to O
12-Week O
Placebo-Controlled O
Clinical O
Trials O
for O
the O
Treatment O
of O
Schizophrenia O
and O
Bipolar O
Mania O
( O
Monotherapy O
) O
Preferred O
Term O
SEROQUEL O
( O
n=719 O
) O
PLACEBO O
( O
n=404 O
) O
Headache B-OSE_Labeled_AE
21 O
% O
14 O
% O
Agitation B-OSE_Labeled_AE
20 O
% O
17 O
% O
Somnolence B-OSE_Labeled_AE
18 O
% O
8 O
% O
Dizziness B-OSE_Labeled_AE
11 O
% O
5 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
9 O
% O
3 O
% O
Constipation B-OSE_Labeled_AE
8 O
% O
3 O
% O
Pain B-OSE_Labeled_AE
7 O
% O
5 O
% O
Tachycardia B-OSE_Labeled_AE
6 O
% O
4 O
% O
Vomiting B-OSE_Labeled_AE
6 O
% O
5 O
% O
Asthenia B-OSE_Labeled_AE
5 O
% O
3 O
% O
Dyspepsia B-OSE_Labeled_AE
5 O
% O
1 O
% O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
5 O
% O
1 O
% O
ALT B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
5 O
% O
1 O
% O
Anxiety B-OSE_Labeled_AE
4 O
% O
3 O
% O
Pharyngitis B-OSE_Labeled_AE
4 O
% O
3 O
% O
Rash B-OSE_Labeled_AE
4 O
% O
2 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
4 O
% O
1 O
% O
Postural B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
4 O
% O
1 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
1 O
% O
AST B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Rhinitis B-OSE_Labeled_AE
3 O
% O
1 O
% O
Fever B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastroenteritis B-OSE_Labeled_AE
2 O
% O
0 O
% O
Amblyopia B-OSE_Labeled_AE
2 O
% O
1 O
% O
In O
the O
acute O
adjunct O
therapy O
of O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
up O
to O
3 O
weeks O
) O
studies O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
observed O
at O
a O
rate O
on O
SEROQUEL O
at O
least O
twice O
that O
of O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
34 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
19 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
pharyngitis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

Table O
10 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
3 O
weeks O
) O
of O
acute B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
ranging O
from O
100 O
to O
800 O
mg/day O
) O
used O
as O
adjunct O
therapy O
to O
lithium O
and O
divalproex O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Table O
10 O
: O
Adverse O
Reaction O
Incidence O
in O
3-Week O
Placebo-Controlled O
Clinical O
Trials O
for O
the O
Treatment O
of O
Bipolar O
Mania O
( O
Adjunct O
Therapy O
) O
Preferred O
Term O
SEROQUEL O
( O
n=196 O
) O
PLACEBO O
( O
n=203 O
) O
Somnolence B-OSE_Labeled_AE
34 O
% O
9 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
19 O
% O
3 O
% O
Headache B-OSE_Labeled_AE
17 O
% O
13 O
% O
Asthenia B-OSE_Labeled_AE
10 O
% O
4 O
% O
Constipation B-OSE_Labeled_AE
10 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
9 O
% O
6 O
% O
Tremor B-OSE_Labeled_AE
8 O
% O
7 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
7 O
% O
3 O
% O
Postural B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
7 O
% O
2 O
% O
Agitation B-OSE_Labeled_AE
6 O
% O
4 O
% O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
6 O
% O
3 O
% O
Pharyngitis B-OSE_Labeled_AE
6 O
% O
3 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
5 O
% O
3 O
% O
Hypertonia B-OSE_Labeled_AE
4 O
% O
3 O
% O
Rhinitis B-OSE_Labeled_AE
4 O
% O
2 O
% O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
4 O
% O
2 O
% O
Twitching B-OSE_Labeled_AE
4 O
% O
1 O
% O
Dyspepsia B-OSE_Labeled_AE
4 O
% O
3 O
% O
Depression B-OSE_Labeled_AE
3 O
% O
2 O
% O
Amblyopia B-OSE_Labeled_AE
3 O
% O
2 O
% O
Speech B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
3 O
% O
1 O
% O
Hypotension B-OSE_Labeled_AE
3 O
% O
1 O
% O
Hormone B-OSE_Labeled_AE
Level I-OSE_Labeled_AE
Altered I-OSE_Labeled_AE
3 O
% O
0 O
% O
Heaviness B-OSE_Labeled_AE
2 O
% O
1 O
% O
Infection B-OSE_Labeled_AE
2 O
% O
1 O
% O
Fever B-OSE_Labeled_AE
2 O
% O
1 O
% O
Hypertension B-OSE_Labeled_AE
2 O
% O
1 O
% O
Tachycardia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
2 O
% O
1 O
% O
Hypothyroidism B-OSE_Labeled_AE
2 O
% O
1 O
% O
Incoordination B-OSE_Labeled_AE
2 O
% O
1 O
% O
Thinking B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
2 O
% O
0 O
% O
Anxiety B-OSE_Labeled_AE
2 O
% O
0 O
% O
Ataxia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Sinusitis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Sweating B-OSE_Labeled_AE
2 O
% O
1 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
2 O
% O
1 O
% O
In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
( O
up O
to O
8 O
weeks O
) O
, O
the O
most O
commonly O
observed O
treatment O
emergent O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
observed O
at O
a O
rate O
on O
SEROQUEL O
at O
least O
twice O
that O
of O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
57 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
44 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
and O
lethargy B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

Table O
11 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
8 O
weeks O
) O
of O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
of O
300 O
and O
600 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Table O
11 O
: O
Adverse O
Reaction O
Incidence O
in O
8-Week O
Placebo-Controlled O
Clinical O
Trials O
for O
the O
Treatment O
of O
Bipolar O
Depression O
Preferred O
Term O
SEROQUEL O
( O
n=698 O
) O
PLACEBO O
( O
n=347 O
) O
Somnolence B-OSE_Labeled_AE
Somnolence O
combines O
adverse O
reaction O
terms O
somnolence B-OSE_Labeled_AE
and O
sedation B-OSE_Labeled_AE
57 O
% O
15 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
44 O
% O
13 O
% O
Dizziness B-OSE_Labeled_AE
18 O
% O
7 O
% O
Constipation B-OSE_Labeled_AE
10 O
% O
4 O
% O
Fatigue B-OSE_Labeled_AE
10 O
% O
8 O
% O
Dyspepsia B-OSE_Labeled_AE
7 O
% O
4 O
% O
Vomiting B-OSE_Labeled_AE
5 O
% O
4 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
5 O
% O
3 O
% O
Lethargy B-OSE_Labeled_AE
5 O
% O
2 O
% O
Nasal B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
5 O
% O
3 O
% O
Orthostatic B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
4 O
% O
3 O
% O
Akathisia B-OSE_Labeled_AE
4 O
% O
1 O
% O
Palpitations B-OSE_Labeled_AE
4 O
% O
1 O
% O
Vision B-OSE_Labeled_AE
Blurred I-OSE_Labeled_AE
4 O
% O
2 O
% O
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
4 O
% O
1 O
% O
Arthralgia B-OSE_Labeled_AE
3 O
% O
2 O
% O
Paraesthesia B-OSE_Labeled_AE
3 O
% O
2 O
% O
Cough B-OSE_Labeled_AE
3 O
% O
1 O
% O
Extrapyramidal B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
3 O
% O
1 O
% O
Irritability B-OSE_Labeled_AE
3 O
% O
1 O
% O
Dysarthria B-OSE_Labeled_AE
3 O
% O
0 O
% O
Hypersomnia B-OSE_Labeled_AE
3 O
% O
0 O
% O
Sinus B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
2 O
% O
1 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
2 O
% O
1 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastroesophageal B-OSE_Labeled_AE
Reflux I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
2 O
% O
1 O
% O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Extremity I-OSE_Labeled_AE
2 O
% O
1 O
% O
Asthenia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Balance B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
2 O
% O
1 O
% O
Hypoesthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Dysphagia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Restless B-OSE_Labeled_AE
Legs I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
2 O
% O
0 O
% O
Explorations O
for O
interactions O
on O
the O
basis O
of O
gender O
, O
age O
, O
and O
race O
did O
not O
reveal O
any O
clinically O
meaningful O
differences O
in O
the O
adverse O
reaction O
occurrence O
on O
the O
basis O
of O
these O
demographic O
factors O
. O

Dose O
Dependency O
of O
Adverse O
Reactions O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Dose-related O
Adverse O
Reactions O
: O
Spontaneously O
elicited O
adverse O
reaction O
data O
from O
a O
study O
of O
schizophrenia B-Not_AE_Candidate
comparing O
five O
fixed O
doses O
of O
SEROQUEL O
( O
75 O
mg O
, O
150 O
mg O
, O
300 O
mg O
, O
600 O
mg O
, O
and O
750 O
mg/day O
) O
to O
placebo O
were O
explored O
for O
dose-relatedness O
of O
adverse O
reactions O
. O

Logistic O
regression O
analyses O
revealed O
a O
positive O
dose O
response O
( O
p O
< O
0.05 O
) O
for O
the O
following O
adverse O
reactions O
: O
dyspepsia B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

Adverse O
Reactions O
in O
clinical O
trials O
with O
quetiapine O
and O
not O
listed O
elsewhere O
in O
the O
label O
: O
The O
following O
adverse O
reactions O
have O
also O
been O
reported O
with O
quetiapine O
: O
nightmares B-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
and O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
( O
not O
associated O
with O
NMS B-NonOSE_AE
) O
, O
galactorrhea B-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
( O
which O
may O
occur O
at O
or O
near O
initiation O
of O
treatment O
and O
be O
associated O
with O
hypotension B-OSE_Labeled_AE
and/ O
or O
syncope B-OSE_Labeled_AE
) O
, O
decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
, O
somnambulism B-OSE_Labeled_AE
( O
and O
other O
related O
events O
) O
, O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
gamma I-OSE_Labeled_AE
- I-OSE_Labeled_AE
GT I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
hypothermia B-OSE_Labeled_AE
, O
and O
priapism B-OSE_Labeled_AE
. O

Extrapyramidal B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EPS I-OSE_Labeled_AE
) O
: O
Dystonia O
Class O
Effect O
: O
Symptoms O
of O
dystonia B-OSE_Labeled_AE
, O
prolonged B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
groups I-OSE_Labeled_AE
, O
may O
occur O
in O
susceptible O
individuals O
during O
the O
first O
few O
days O
of O
treatment O
. O

Dystonic B-NonOSE_AE
symptoms I-NonOSE_AE
include O
: O
spasm B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
muscles I-NonOSE_AE
, O
sometimes O
progressing O
to O
tightness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
throat I-NonOSE_AE
, O
swallowing B-NonOSE_AE
difficulty I-NonOSE_AE
, O
difficulty B-NonOSE_AE
breathing I-NonOSE_AE
, O
and/or O
protrusion B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
tongue I-NonOSE_AE
. O

While O
these O
symptoms O
can O
occur O
at O
low O
doses O
, O
they O
occur O
more O
frequently O
and O
with O
greater O
severity O
with O
high O
potency O
and O
at O
higher O
doses O
of O
first O
generation O
antipsychotic O
drugs O
. O

An O
elevated O
risk O
of O
acute B-NonOSE_AE
dystonia I-NonOSE_AE
is O
observed O
in O
males O
and O
younger O
age O
groups O
. O

Four O
methods O
were O
used O
to O
measure O
EPS B-NonOSE_AE
: O
( O
1 O
) O
Simpson-Angus O
total O
score O
( O
mean O
change O
from O
baseline O
) O
which O
evaluates O
Parkinsonism B-NonOSE_AE
and O
akathisia B-NonOSE_AE
, O
( O
2 O
) O
Barnes O
Akathisia B-NonOSE_AE
Rating O
Scale O
( O
BARS O
) O
Global O
Assessment O
Score O
, O
( O
3 O
) O
incidence O
of O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
( O
akathisia B-NonOSE_AE
, O
akinesia B-NonOSE_AE
, O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
extrapyramidal B-NonOSE_AE
syndrome I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
hypokinesia B-NonOSE_AE
, O
neck B-NonOSE_AE
rigidity I-NonOSE_AE
, O
and O
tremor B-NonOSE_AE
) O
, O
and O
( O
4 O
) O
use O
of O
anticholinergic O
medications O
to O
treat O
emergent O
EPS B-NonOSE_AE
. O

Adults O
: O
Data O
from O
one O
6-week O
clinical O
trial O
of O
schizophrenia B-Not_AE_Candidate
comparing O
five O
fixed O
doses O
of O
SEROQUEL O
( O
75 O
, O
150 O
, O
300 O
, O
600 O
, O
750 O
mg/day O
) O
provided O
evidence O
for O
the O
lack O
of O
treatment-emergent O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
and O
dose-relatedness O
for O
EPS B-NonOSE_AE
associated O
with O
SEROQUEL O
treatment O
. O

Three O
methods O
were O
used O
to O
measure O
EPS B-NonOSE_AE
: O
( O
1 O
) O
Simpson-Angus O
total O
score O
( O
mean O
change O
from O
baseline O
) O
which O
evaluates O
Parkinsonism B-NonOSE_AE
and O
akathisia B-NonOSE_AE
, O
( O
2 O
) O
incidence O
of O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
( O
akathisia B-NonOSE_AE
, O
akinesia B-NonOSE_AE
, O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
extrapyramidal B-NonOSE_AE
syndrome I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
hypokinesia B-NonOSE_AE
, O
neck B-NonOSE_AE
rigidity I-NonOSE_AE
, O
and O
tremor B-NonOSE_AE
) O
, O
and O
( O
3 O
) O
use O
of O
anticholinergic O
medications O
to O
treat O
emergent O
EPS B-NonOSE_AE
. O

In O
Table O
12 O
, O
dystonic B-NonOSE_AE
event I-NonOSE_AE
included O
nuchal B-NonOSE_AE
rigidity I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
dystonia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
oculogyration B-NonOSE_AE
; O
parkinsonism B-NonOSE_AE
included O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
tremor B-NonOSE_AE
, O
drooling B-NonOSE_AE
, O
hypokinesia B-NonOSE_AE
; O
akathisia B-NonOSE_AE
included O
akathisia B-NonOSE_AE
, O
psychomotor B-NonOSE_AE
agitation I-NonOSE_AE
; O
dyskinetic B-NonOSE_AE
event I-NonOSE_AE
included O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
dyskinesia B-NonOSE_AE
, O
choreoathetosis B-NonOSE_AE
; O
and O
other O
extrapyramidal B-NonOSE_AE
event I-NonOSE_AE
included O
restlessness B-NonOSE_AE
, O
extrapyramidal B-NonOSE_AE
disorder I-NonOSE_AE
, O
movement B-NonOSE_AE
disorder I-NonOSE_AE
. O

Table O
12 O
: O
Adverse O
Reactions O
Associated O
with O
EPS O
in O
a O
Short-Term O
, O
Placebo-Controlled O
Multiple O
Fixed-Dose O
Phase O
III O
Schizophrenia O
Trial O
( O
6 O
weeks O
duration O
) O
Preferred O
Term O
SEROQUEL O
75 O
mg/day O
( O
N=53 O
) O
SEROQUEL O
150 O
mg/day O
( O
N=48 O
) O
SEROQUEL O
300 O
mg/day O
( O
N=52 O
) O
SEROQUEL O
600 O
mg/day O
( O
N=51 O
) O
SEROQUEL O
750 O
mg/day O
( O
N=54 O
) O
Placebo O
( O
N=51 O
) O
n O
% O
n O
% O
n O
% O
n O
% O
n O
% O
n O
% O
Dystonic B-NonOSE_AE
event I-NonOSE_AE
2 O
3.8 O
2 O
4.2 O
0 O
0.0 O
2 O
3.9 O
3 O
5.6 O
4 O
7.8 O
Parkinsonism B-NonOSE_AE
2 O
3.8 O
0 O
0.0 O
1 O
1.9 O
1 O
2.0 O
1 O
1.9 O
4 O
7.8 O
Akathisia B-NonOSE_AE
1 O
1.9 O
1 O
2.1 O
0 O
0.0 O
0 O
0.0 O
1 O
1.9 O
4 O
7.8 O
Dyskinetic B-NonOSE_AE
event I-NonOSE_AE
2 O
3.8 O
0 O
0.0 O
0 O
0.0 O
1 O
2.0 O
0 O
0.0 O
0 O
0.0 O
Other O
extrapyramidal B-NonOSE_AE
event I-NonOSE_AE
2 O
3.8 O
0 O
0.0 O
3 O
5.8 O
3 O
5.9 O
1 O
1.9 O
4 O
7.8 O
Parkinsonism B-NonOSE_AE
incidence O
rates O
as O
measured O
by O
the O
Simpson-Angus O
total O
score O
for O
placebo O
and O
the O
five O
fixed O
doses O
( O
75 O
, O
150 O
, O
300 O
, O
600 O
, O
750 O
mg/day O
) O
were O
: O
-0.6 O
; O
-1.0 O
, O
-1.2 O
; O
-1.6 O
; O
-1.8 O
and O
-1.8 O
. O

The O
rate O
of O
anticholinergic O
medication O
use O
to O
treat O
emergent O
EPS B-NonOSE_AE
for O
placebo O
and O
the O
five O
fixed O
doses O
was O
: O
14 O
% O
; O
11 O
% O
; O
10 O
% O
; O
8 O
% O
; O
12 O
% O
and O
11 O
% O
. O

In O
six O
additional O
placebo-controlled O
clinical O
trials O
( O
3 O
in O
acute O
mania B-Not_AE_Candidate
and O
3 O
in O
schizophrenia B-Not_AE_Candidate
) O
using O
variable O
doses O
of O
SEROQUEL O
, O
there O
were O
no O
differences O
between O
the O
SEROQUEL O
and O
placebo O
treatment O
groups O
in O
the O
incidence O
of O
EPS B-NonOSE_AE
, O
as O
assessed O
by O
Simpson-Angus O
total O
scores O
, O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
and O
the O
use O
of O
concomitant O
anticholinergic O
medications O
to O
treat O
EPS B-NonOSE_AE
. O

In O
two O
placebo-controlled O
clinical O
trials O
for O
the O
treatment O
of O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
using O
300 O
mg O
and O
600 O
mg O
of O
SEROQUEL O
, O
the O
incidence O
of O
adverse O
reactions O
potentially O
related O
to O
EPS B-OSE_Labeled_AE
was O
12 O
% O
in O
both O
dose O
groups O
and O
6 O
% O
in O
the O
placebo O
group O
. O

In O
these O
studies O
, O
the O
incidence O
of O
the O
individual O
adverse O
reactions O
( O
akathisia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
involuntary I-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
and O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
) O
were O
generally O
low O
and O
did O
not O
exceed O
4 O
% O
in O
any O
treatment O
group O
. O

The O
3 O
treatment O
groups O
were O
similar O
in O
mean O
change O
in O
SAS O
total O
score O
and O
BARS O
Global O
Assessment O
score O
at O
the O
end O
of O
treatment O
. O

The O
use O
of O
concomitant O
anticholinergic O
medications O
was O
infrequent O
and O
similar O
across O
the O
three O
treatment O
groups O
. O

Children O
and O
Adolescents O
The O
information O
below O
is O
derived O
from O
a O
clinical O
trial O
database O
for O
SEROQUEL O
consisting O
of O
over O
1000 O
pediatric O
patients O
. O

This O
database O
includes O
677 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
and O
393 O
children O
and O
adolescents O
( O
10-17 O
years O
old O
) O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Schizophrenia B-Not_AE_Candidate
: O
The O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
for O
quetiapine-treated O
and O
placebo-treated O
patients O
was O
8.2 O
% O
and O
2.7 O
% O
, O
respectively O
. O

The O
adverse O
event O
leading O
to O
discontinuation O
in O
1 O
% O
or O
more O
of O
patients O
on O
SEROQUEL O
and O
at O
a O
greater O
incidence O
than O
placebo O
was O
somnolence B-OSE_Labeled_AE
( O
2.7 O
% O
and O
0 O
% O
for O
placebo O
) O
. O

Bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
Mania I-Not_AE_Candidate
: O
The O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
for O
quetiapine-treated O
and O
placebo-treated O
patients O
was O
11.4 O
% O
and O
4.4 O
% O
, O
respectively O
. O

The O
adverse O
reactions O
leading O
to O
discontinuation O
in O
2 O
% O
or O
more O
of O
patients O
on O
SEROQUEL O
and O
at O
a O
greater O
incidence O
than O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
4.1 O
% O
vs O
. O
1.1 O
% O
) O
and O
fatigue B-OSE_Labeled_AE
( O
2.1 O
% O
vs O
. O
0 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
In O
therapy O
for O
schizophrenia B-Not_AE_Candidate
( O
up O
to O
6 O
weeks O
) O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
quetiapine O
in O
adolescents O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
quetiapine O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
were O
somnolence B-OSE_Labeled_AE
( O
34 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
7 O
% O
) O
. O

In O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
therapy O
( O
up O
to O
3 O
weeks O
) O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
quetiapine O
in O
children O
and O
adolescents O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
quetiapine O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
were O
somnolence B-OSE_Labeled_AE
( O
53 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

In O
an O
acute O
( O
8-week O
) O
SEROQUEL O
XR O
trial O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
XR O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
at O
least O
twice O
that O
for O
placebo O
) O
were O
dizziness B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
5 O
% O
) O
and O
nausea B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
> O
= O
2 O
% O
among O
SEROQUEL O
Treated O
Patients O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Schizophrenia B-Not_AE_Candidate
( O
Adolescents O
, O
13- O
17 O
years O
old O
) O
The O
following O
findings O
were O
based O
on O
a O
6-week O
placebo-controlled O
trial O
in O
which O
quetiapine O
was O
administered O
in O
either O
doses O
of O
400 O
or O
800 O
mg/day O
. O

Table O
13 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
treatment-emergent O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
6 O
weeks O
) O
of O
schizophrenia B-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
of O
400 O
or O
800 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
at O
least O
twice O
the O
incidence O
in O
placebo-treated O
patients O
. O

Adverse O
events O
that O
were O
potentially O
dose-related O
with O
higher O
frequency O
in O
the O
800 O
mg O
group O
compared O
to O
the O
400 O
mg O
group O
included O
dizziness B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
15 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
10 O
% O
) O
, O
and O
tachycardia B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
11 O
% O
) O
. O

Table O
13 O
: O
Adverse O
Reaction O
Incidence O
in O
a O
6-Week O
Placebo-Controlled O
Clinical O
Trial O
for O
the O
Treatment O
of O
Schizophrenia O
in O
Adolescent O
Patients O
Preferred O
Term O
SEROQUEL O
400 O
mg O
( O
n=73 O
) O
SEROQUEL800 O
mg O
( O
n=74 O
) O
Placebo O
( O
n=75 O
) O
Somnolence B-OSE_Labeled_AE
Somnolence O
combines O
adverse O
reaction O
terms O
somnolence B-OSE_Labeled_AE
and O
sedation B-OSE_Labeled_AE
. O

33 O
% O
35 O
% O
11 O
% O
Dizziness B-OSE_Labeled_AE
8 O
% O
15 O
% O
5 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
4 O
% O
10 O
% O
1 O
% O
Tachycardia B-OSE_Labeled_AE
Tachycardia O
combines O
adverse O
reaction O
terms O
tachycardia B-OSE_Labeled_AE
and O
sinus B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
. O

6 O
% O
11 O
% O
0 O
% O
Irritability B-OSE_Labeled_AE
3 O
% O
5 O
% O
0 O
% O
Arthralgia B-OSE_Labeled_AE
1 O
% O
3 O
% O
0 O
% O
Asthenia B-OSE_Labeled_AE
1 O
% O
3 O
% O
1 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
1 O
% O
3 O
% O
0 O
% O
Dyspnea B-OSE_Labeled_AE
0 O
% O
3 O
% O
0 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
1 O
% O
0 O
% O
Anorexia B-OSE_Labeled_AE
3 O
% O
1 O
% O
0 O
% O
Tooth B-OSE_Labeled_AE
Abscess I-OSE_Labeled_AE
3 O
% O
1 O
% O
0 O
% O
Dyskinesia B-OSE_Labeled_AE
3 O
% O
0 O
% O
0 O
% O
Epistaxis B-OSE_Labeled_AE
3 O
% O
0 O
% O
1 O
% O
Muscle B-OSE_Labeled_AE
Rigidity I-OSE_Labeled_AE
3 O
% O
0 O
% O
0 O
% O
Bipolar O
I O
Mania O
( O
Children O
and O
Adolescents O
10 O
to O
17 O
years O
old O
) O
The O
following O
findings O
were O
based O
on O
a O
3-week O
placebo-controlled O
trial O
in O
which O
quetiapine O
was O
administered O
in O
either O
doses O
of O
400 O
or O
600 O
mg/day O
. O

Commonly O
Observed O
Adverse O
Reactions O
In O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
therapy O
( O
up O
to O
3 O
weeks O
) O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
quetiapine O
in O
children O
and O
adolescents O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
quetiapine O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
were O
somnolence B-OSE_Labeled_AE
( O
53 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

Table O
14 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
treatment-emergent O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
3 O
weeks O
) O
of O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
of O
400 O
or O
600 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Adverse O
events O
that O
were O
potentially O
dose-related O
with O
higher O
frequency O
in O
the O
600 O
mg O
group O
compared O
to O
the O
400 O
mg O
group O
included O
somnolence B-OSE_Labeled_AE
( O
50 O
% O
vs O
. O
57 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
10 O
% O
) O
and O
tachycardia B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
9 O
% O
) O
. O

Table O
14 O
: O
Adverse O
Reactions O
in O
a O
3-Week O
Placebo-Controlled O
Clinical O
Trial O
for O
the O
Treatment O
of O
Bipolar O
Mania O
in O
Children O
and O
Adolescent O
Patients O
Preferred O
Term O
SEROQUEL O
400 O
mg O
( O
n=95 O
) O
SEROQUEL O
600 O
mg O
( O
n=98 O
) O
Placebo O
( O
n=90 O
) O
Somnolence B-OSE_Labeled_AE
Somnolence O
combines O
adverse O
reactions O
terms O
somnolence B-OSE_Labeled_AE
and O
sedation B-OSE_Labeled_AE
. O

50 O
% O
57 O
% O
14 O
% O
Dizziness B-OSE_Labeled_AE
19 O
% O
17 O
% O
2 O
% O
Nausea B-OSE_Labeled_AE
6 O
% O
10 O
% O
4 O
% O
Fatigue B-OSE_Labeled_AE
14 O
% O
9 O
% O
4 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
10 O
% O
9 O
% O
1 O
% O
Tachycardia B-OSE_Labeled_AE
Tachycardia O
combines O
adverse O
reaction O
terms O
tachycardia B-OSE_Labeled_AE
and O
sinus B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
. O

6 O
% O
9 O
% O
1 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
7 O
% O
7 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
8 O
% O
7 O
% O
3 O
% O
Nasal B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
3 O
% O
6 O
% O
2 O
% O
Weight B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
6 O
% O
6 O
% O
0 O
% O
Irritability B-OSE_Labeled_AE
3 O
% O
5 O
% O
1 O
% O
Pyrexia B-OSE_Labeled_AE
1 O
% O
4 O
% O
1 O
% O
Aggression B-OSE_Labeled_AE
1 O
% O
3 O
% O
0 O
% O
Musculoskeletal B-OSE_Labeled_AE
Stiffness I-OSE_Labeled_AE
1 O
% O
3 O
% O
1 O
% O
Accidental B-OSE_Labeled_AE
Overdose I-OSE_Labeled_AE
0 O
% O
2 O
% O
0 O
% O
Acne B-OSE_Labeled_AE
3 O
% O
2 O
% O
0 O
% O
Arthralgia B-OSE_Labeled_AE
4 O
% O
2 O
% O
1 O
% O
Lethargy B-OSE_Labeled_AE
2 O
% O
2 O
% O
0 O
% O
Pallor B-OSE_Labeled_AE
1 O
% O
2 O
% O
0 O
% O
Stomach B-OSE_Labeled_AE
Discomfort I-OSE_Labeled_AE
4 O
% O
2 O
% O
1 O
% O
Syncope B-OSE_Labeled_AE
2 O
% O
2 O
% O
0 O
% O
Vision B-OSE_Labeled_AE
Blurred I-OSE_Labeled_AE
3 O
% O
2 O
% O
0 O
% O
Constipation B-OSE_Labeled_AE
4 O
% O
2 O
% O
0 O
% O
Ear B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
0 O
% O
0 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
0 O
% O
0 O
% O
Sinus B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
3 O
% O
0 O
% O
0 O
% O
Thirst B-OSE_Labeled_AE
2 O
% O
0 O
% O
0 O
% O
Extrapyramidal O
Symptoms O
: O
In O
a O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
, O
the O
aggregated O
incidence O
of O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
was O
12.9 O
% O
( O
19/147 O
) O
for O
SEROQUEL O
and O
5.3 O
% O
( O
4/75 O
) O
for O
placebo O
, O
though O
the O
incidence O
of O
the O
individual O
adverse O
events O
( O
akathisia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
) O
did O
not O
exceed O
4.1 O
% O
in O
any O
treatment O
group O
. O

In O
a O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
children O
and O
adolescent O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
, O
the O
aggregated O
incidence O
of O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
was O
3.6 O
% O
( O
7/193 O
) O
or O
SEROQUEL O
and O
1.1 O
% O
( O
1/90 O
) O
for O
placebo O
. O

Table O
15 O
presents O
a O
listing O
of O
patients O
with O
adverse O
reactions O
potentially O
associated O
with O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
in O
the O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
. O

In O
Tables O
15 O
- O
16 O
dystonic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
included O
nuchal B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
and O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
; O
parkinsonism B-OSE_Labeled_AE
included O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
and O
tremor B-OSE_Labeled_AE
; O
akathisia B-OSE_Labeled_AE
included O
akathisia B-OSE_Labeled_AE
only O
dyskinetic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
included O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
; O
and O
choreoathetosis B-OSE_Labeled_AE
; O
and O
other O
extrapyramidal B-OSE_Labeled_AE
event I-OSE_Labeled_AE
included O
restlessness B-OSE_Labeled_AE
and O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Table O
15 O
: O
Adverse O
Reactions O
Associated O
with O
Extrapyramidal O
Symptoms O
in O
the O
Placebo-Controlled O
Trial O
in O
Adolescent O
Patients O
with O
Schizophrenia O
( O
6-week O
duration O
) O
Preferred O
Term O
SEROQUEL O
400 O
mg/day O
( O
N=73 O
) O
SEROQUEL O
800 O
mg/day O
( O
N=74 O
) O
All O
SEROQUEL O
( O
N=147 O
) O
Placebo O
( O
N=75 O
) O
n O
% O
n O
% O
n O
% O
n O
% O
Dystonic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
2 O
2.7 O
0 O
0.0 O
2 O
1.4 O
0 O
0.0 O
Parkinsonism B-OSE_Labeled_AE
4 O
5.5 O
4 O
5.4 O
8 O
5.4 O
2 O
2.7 O
Akathisia B-OSE_Labeled_AE
3 O
4.1 O
4 O
5.4 O
7 O
4.8 O
3 O
4.0 O
Dyskinetic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
2 O
2.7 O
0 O
0.0 O
2 O
1.4 O
0 O
0.0 O
Other O
Extrapyramidal B-OSE_Labeled_AE
Event I-OSE_Labeled_AE
2 O
2.7 O
2 O
2.7 O
4 O
2.7 O
0 O
0.0 O
Table O
16 O
presents O
a O
listing O
of O
patients O
with O
adverse O
reactions O
associated O
with O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
in O
a O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
children O
and O
adolescent O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
. O

Table O
16 O
: O
Adverse O
Reactions O
Associated O
with O
Extrapyramidal O
Symptoms O
in O
a O
Placebo-Controlled O
Trial O
in O
Children O
and O
Adolescent O
Patients O
with O
Bipolar O
I O
Mania O
( O
3-week O
duration O
) O
Preferred O
TermThere O
were O
no O
adverse O
experiences O
with O
the O
preferred O
term O
of O
dystonic B-NonOSE_AE
or O
dyskinetic B-NonOSE_AE
events I-NonOSE_AE
. O

SEROQUEL O
400 O
mg/day O
( O
N=95 O
) O
SEROQUEL O
600 O
mg/day O
( O
N=98 O
) O
All O
SEROQUEL O
( O
N=193 O
) O
Placebo O
( O
N=90 O
) O
n O
% O
n O
% O
n O
% O
n O
% O
Parkinsonism B-OSE_Labeled_AE
2 O
2.1 O
1 O
1.0 O
3 O
1.6 O
1 O
1.1 O
Akathisia B-OSE_Labeled_AE
1 O
1.0 O
1 O
1.0 O
2 O
1.0 O
0 O
0.0 O
Other O
Extrapyramidal B-OSE_Labeled_AE
Event I-OSE_Labeled_AE
1 O
1.1 O
1 O
1.0 O
2 O
1.0 O
0 O
0.0 O
Other O
Adverse O
Reactions O
Observed O
During O
the O
Pre-Marketing O
Evaluation O
of O
SEROQUEL O
Following O
is O
a O
list O
of O
COSTART O
terms O
that O
reflect O
treatment-emergent O
adverse O
reactions O
as O
defined O
in O
the O
introduction O
to O
the O
ADVERSE O
REACTIONS O
section O
reported O
by O
patients O
treated O
with O
SEROQUEL O
at O
multiple O
doses O
> O
75 O
mg/day O
during O
any O
phase O
of O
a O
trial O
within O
the O
premarketing O
database O
of O
approximately O
2200 O
patients O
treated O
for O
schizophrenia B-Not_AE_Candidate
. O

All O
reported O
reactions O
are O
included O
except O
those O
already O
listed O
in O
the O
tables O
or O
elsewhere O
in O
labeling O
, O
those O
reactions O
for O
which O
a O
drug O
cause O
was O
remote O
, O
and O
those O
reaction O
terms O
which O
were O
so O
general O
as O
to O
be O
uninformative O
. O

It O
is O
important O
to O
emphasize O
that O
, O
although O
the O
reactions O
reported O
occurred O
during O
treatment O
with O
SEROQUEL O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Reactions O
are O
further O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
frequent O
adverse O
reactions O
are O
those O
occurring O
in O
at O
least O
1/100 O
patients O
( O
only O
those O
not O
already O
listed O
in O
the O
tabulated O
results O
from O
placebo-controlled O
trials O
appear O
in O
this O
listing O
) O
; O
infrequent O
adverse O
reactions O
are O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
; O
rare O
reactions O
are O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
involuntary B-OSE_Labeled_AE
movements I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
stupor B-OSE_Labeled_AE
, O
bruxism B-OSE_Labeled_AE
, O
catatonic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
hemiplegia B-OSE_Labeled_AE
; O
aphasia B-OSE_Labeled_AE
, O
buccoglossal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
choreoathetosis B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
stuttering B-OSE_Labeled_AE
, O
subdural B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Frequent O
: O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
; O
Infrequent O
: O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
suicide O
attempt O
, O
malaise B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
; O
Rare O
: O
abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Frequent O
: O
anorexia B-OSE_Labeled_AE
; O
Infrequent O
: O
increased B-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
gamma B-OSE_Labeled_AE
glutamyl I-OSE_Labeled_AE
transpeptidase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
gingivitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
hemorrhoids B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
caries I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
; O
Rare O
: O
glossitis B-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
vasodilatation B-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
interval I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
irregular B-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
, O
T B-OSE_Labeled_AE
wave I-OSE_Labeled_AE
abnormality I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
T B-OSE_Labeled_AE
wave I-OSE_Labeled_AE
inversion I-OSE_Labeled_AE
; O
Rare O
: O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
AV B-OSE_Labeled_AE
block I-OSE_Labeled_AE
first I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
ST B-OSE_Labeled_AE
elevated I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
T B-OSE_Labeled_AE
wave I-OSE_Labeled_AE
flattening I-OSE_Labeled_AE
, O
ST B-OSE_Labeled_AE
abnormality I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
QRS I-OSE_Labeled_AE
duration I-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Frequent O
: O
cough B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
; O
Infrequent O
: O
pneumonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
asthma B-OSE_Labeled_AE
; O
Rare O
: O
hiccup B-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
alcohol B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
; O
Rare O
: O
glycosuria B-OSE_Labeled_AE
, O
gout B-OSE_Labeled_AE
, O
hand B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
water B-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
pruritus B-OSE_Labeled_AE
, O
acne B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
; O
Rare O
: O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
psoriasis B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
dysmenorrheal B-OSE_Labeled_AE
[ O
note O
: O
Adjusted O
for O
gender O
. O
] O

, O
vaginitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
, O
impotence B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
lactation I-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
vulvovaginitis B-OSE_Labeled_AE
, O
orchitis B-OSE_Labeled_AE
; O
gynecomastia B-OSE_Labeled_AE
, O
nocturia B-OSE_Labeled_AE
, O
polyuria B-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Infrequent O
: O
conjunctivitis B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eyes I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
, O
blepharitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
Rare O
: O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
pathological B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
, O
twitching B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
leukocytosis B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
eosinophilia B-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
; O
lymphadenopathy B-OSE_Labeled_AE
, O
cyanosis B-OSE_Labeled_AE
; O
Rare O
: O
hemolysis B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Endocrine B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
hypothyroidism B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
; O
Rare O
: O
hyperthyroidism B-OSE_Labeled_AE
. O

Laboratory O
, O
ECG O
and O
vital O
sign O
changes O
observed O
in O
clinical O
studies O
Laboratory O
Changes O
: O
Neutrophil O
Counts O
Adults O
: O
In O
placebo-controlled O
monotherapy O
clinical O
trials O
involving O
3368 O
patients O
on O
quetiapine O
fumarate O
and O
1515 O
on O
placebo O
, O
the O
incidence O
of O
at O
least O
one O
occurrence O
of O
neutrophil B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
x I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
among O
patients O
with O
a O
normal O
baseline O
neutrophil O
count O
and O
at O
least O
one O
available O
follow O
up O
laboratory O
measurement O
was O
0.3 O
% O
( O
10/2967 O
) O
in O
patients O
treated O
with O
quetiapine O
fumarate O
, O
compared O
to O
0.1 O
% O
( O
2/1349 O
) O
in O
patients O
treated O
with O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

Transaminase O
Elevations O
Adults O
: O
Asymptomatic O
, O
transient O
and O
reversible O
elevations B-OSE_Labeled_AE
in O
serum O
transaminases O
( O
primarily O
ALT I-OSE_Labeled_AE
) O
have O
been O
reported O
. O

In O
schizophrenia B-Not_AE_Candidate
trials O
in O
adults O
, O
the O
proportions O
of O
patients O
with O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
> O
3 O
times O
the O
upper O
limits O
of O
the O
normal O
reference O
range O
in O
a O
pool O
of O
3- O
to O
6-week O
placebo-controlled O
trials O
were O
approximately O
6 O
% O
( O
29/483 O
) O
for O
SEROQUEL O
compared O
to O
1 O
% O
( O
3/194 O
) O
for O
placebo O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
in O
adults O
, O
the O
proportions O
of O
patients O
with O
transaminase B-NonOSE_AE
elevations I-NonOSE_AE
of O
> O
3 O
times O
the O
upper O
limits O
of O
the O
normal O
reference O
range O
in O
a O
pool O
of O
3- O
to O
12-week O
placebo-controlled O
trials O
were O
approximately O
1 O
% O
for O
both O
SEROQUEL O
( O
3/560 O
) O
and O
placebo O
( O
3/294 O
) O
. O

These O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
usually O
occurred O
within O
the O
first O
3 O
weeks O
of O
drug O
treatment O
and O
promptly O
returned O
to O
pre-study O
levels O
with O
ongoing O
treatment O
with O
SEROQUEL O
. O

In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
trials O
, O
the O
proportions O
of O
patients O
with O
transaminase B-NonOSE_AE
elevations I-NonOSE_AE
of O
> O
3 O
times O
the O
upper O
limits O
of O
the O
normal O
reference O
range O
in O
two O
8-week O
placebo-controlled O
trials O
was O
1 O
% O
( O
5/698 O
) O
for O
SEROQUEL O
and O
2 O
% O
( O
6/347 O
) O
for O
placebo O
. O

Decreased O
Hemoglobin O
Adults O
: O
In O
short-term O
placebo-controlled O
trials O
, O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
< O
= O
13 O
g/dL O
males O
, O
< O
= O
12 O
g/dL O
females O
on O
at O
least O
one O
occasion O
occurred O
in O
8.3 O
% O
( O
594/7155 O
) O
of O
quetiapine-treated O
patients O
compared O
to O
6.2 O
% O
( O
219/3536 O
) O
of O
patients O
treated O
with O
placebo O
. O

In O
a O
database O
of O
controlled O
and O
uncontrolled O
clinical O
trials O
, O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
< O
= O
13 O
g/dL O
males O
, O
< O
= O
12 O
g/dL O
females O
on O
at O
least O
one O
occasion O
occurred O
in O
11 O
% O
( O
2277/20729 O
) O
of O
quetiapine-treated O
patients O
. O

Interference O
with O
Urine O
Drug O
Screens O
There O
have O
been O
literature O
reports O
suggesting O
false B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
results I-OSE_Labeled_AE
in I-OSE_Labeled_AE
urine I-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
immunoassays I-OSE_Labeled_AE
for O
methadone O
and O
tricyclic O
antidepressants O
in O
patients O
who O
have O
taken O
quetiapine O
. O

Caution O
should O
be O
exercised O
in O
the O
interpretation O
of O
positive B-OSE_Labeled_AE
urine I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
screen I-OSE_Labeled_AE
results I-OSE_Labeled_AE
for O
these O
drugs O
, O
and O
confirmation O
by O
alternative O
analytical O
technique O
( O
e.g. O
, O
chromatographic O
methods O
) O
should O
be O
considered O
. O

ECG O
Changes O
Adults O
: O
Between-group O
comparisons O
for O
pooled O
placebo-controlled O
trials O
revealed O
no O
statistically O
significant O
SEROQUEL/placebo O
differences O
in O
the O
proportions O
of O
patients O
experiencing O
potentially O
important O
changes B-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
, O
including O
QT O
, O
QTc O
, O
and O
PR O
intervals O
. O

However O
, O
the O
proportions O
of O
patients O
meeting O
the O
criteria O
for O
tachycardia B-OSE_Labeled_AE
were O
compared O
in O
four O
3- O
to O
6-week O
placebo-controlled O
clinical O
trials O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
revealing O
a O
1 O
% O
( O
4/399 O
) O
incidence O
for O
SEROQUEL O
compared O
to O
0.6 O
% O
( O
1/156 O
) O
incidence O
for O
placebo O
. O

In O
acute O
( O
monotherapy O
) O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
the O
proportions O
of O
patients O
meeting O
the O
criteria O
for O
tachycardia B-OSE_Labeled_AE
was O
0.5 O
% O
( O
1/192 O
) O
for O
SEROQUEL O
compared O
to O
0 O
% O
( O
0/178 O
) O
incidence O
for O
placebo O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
adjunct O
) O
trials O
the O
proportions O
of O
patients O
meeting O
the O
same O
criteria O
was O
0.6 O
% O
( O
1/166 O
) O
for O
SEROQUEL O
compared O
to O
0 O
% O
( O
0/171 O
) O
incidence O
for O
placebo O
. O

In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
trials O
, O
no O
patients O
had O
heart B-NonOSE_AE
rate I-NonOSE_AE
increases I-NonOSE_AE
to O
> O
120 O
beats O
per O
minute O
. O

SEROQUEL O
use O
was O
associated O
with O
a O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
assessed O
by O
ECG O
, O
of O
7 O
beats O
per O
minute O
compared O
to O
a O
mean O
increase O
of O
1 O
beat O
per O
minute O
among O
placebo O
patients O
. O

This O
slight O
tendency O
to O
tachycardia B-NonOSE_AE
in O
adults O
may O
be O
related O
to O
SEROQUEL O
's O
potential O
for O
inducing O
orthostatic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

Children O
and O
Adolescents O
: O
In O
the O
acute O
( O
6 O
week O
) O
schizophrenia B-Not_AE_Candidate
trial O
in O
adolescents O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
> O
110 O
bpm O
) O
occurred O
in O
5.2 O
% O
( O
3/73 O
) O
of O
patients O
receiving O
SEROQUEL O
400 O
mg O
and O
8.5 O
% O
( O
5/74 O
) O
of O
patients O
receiving O
SEROQUEL O
800 O
mg O
compared O
to O
0 O
% O
( O
0/75 O
) O
of O
patients O
receiving O
placebo O
. O

Mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
3.8 O
bpm O
and O
11.2 O
bpm O
for O
SEROQUEL O
400 O
mg O
and O
800 O
mg O
groups O
, O
respectively O
, O
compared O
to O
a O
decrease O
of O
3.3 O
bpm O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

In O
the O
acute O
( O
3 O
week O
) O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trial O
in O
children O
and O
adolescents O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
> O
110 O
bpm O
) O
occurred O
in O
1.1 O
% O
( O
1/89 O
) O
of O
patients O
receiving O
SEROQUEL O
400 O
mg O
and O
4.7 O
% O
( O
4/85 O
) O
of O
patients O
receiving O
SEROQUEL O
600 O
mg O
compared O
to O
0 O
% O
( O
0/98 O
) O
of O
patients O
receiving O
placebo O
. O

Mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
12.8 O
bpm O
and O
13.4 O
bpm O
for O
SEROQUEL O
400 O
mg O
and O
600 O
mg O
groups O
, O
respectively O
, O
compared O
to O
a O
decrease O
of O
1.7 O
bpm O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

In O
an O
acute O
( O
8-week O
) O
SEROQUEL O
XR O
trial O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
> O
110 O
bpm O
10-12 O
years O
and O
13-17 O
years O
) O
occurred O
in O
0 O
% O
of O
patients O
receiving O
SEROQUEL O
XR O
and O
1.2 O
% O
of O
patients O
receiving O
placebo O
. O

Mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
3.4 O
bpm O
for O
SEROQUEL O
XR O
, O
compared O
to O
0.3 O
bpm O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
were O
identified O
during O
post O
approval O
of O
SEROQUEL O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
reported O
since O
market O
introduction O
which O
were O
temporally O
related O
to O
quetiapine O
therapy O
include O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
cardiomyopathy B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
hyponatremia B-OSE_Labeled_AE
, O
myocarditis B-OSE_Labeled_AE
, O
nocturnal B-OSE_Labeled_AE
enuresis I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
retrograde B-OSE_Labeled_AE
amnesia I-OSE_Labeled_AE
, O
rhabdomyolysis B-OSE_Labeled_AE
, O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SJS I-OSE_Labeled_AE
) O
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
. O

